🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Gland Pharma Limited GLAND NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.glandpharma.com
Company Profile ↓
₹2,495.00
+36.56% 1Y
Mkt Cap₹41,106.73 Cr
P/E40.06
P/B3.91
Div. Yield0.81%
52W High₹2,550.00
52W Low₹1,596.80
Book Value₹628.68
EPS (TTM)₹62.28

Company Overview

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 21.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 16.0%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹6,430.65 Cr (+14.5% YoY); net profit ₹1,027.32 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +14.5%, earnings +47.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 21.4%, profit CAGR 9.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:21.43%
1 Year:14.50%

Compounded Profit Growth

5 Years:9.57%
1 Year:47.07%

Stock Price Performance

1 Year:+36.56%
6 Months:+47.22%
3 Months:+43.75%
1 Month:+12.74%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 94% of range
₹1,596.80 ₹2,550.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.18 · Neutral
Price Performance
1M+12.74%
3M+43.75%
6M+47.22%
1Y+36.56%
Valuation vs Sector

P/E of 40.06 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 21.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
40.06
Industry PE
39.97
Forward P/E
27.36
PEG Ratio
-
Book Value
₹628.68
Price to Book
3.91
P/S
6.31
EV/EBITDA
22.95
Dividend Yield
0.81%

Growth (CAGR)

Revenue 5Y
21.43%
Profit 5Y
9.57%
Revenue (YoY)
14.50%
Earnings (YoY)
47.07%

Profitability & Returns

ROCE
13.74%
ROE
9.92%
ROA
8.21%
Profit Margin
15.98%
Op Margin
18.75%
Gross Margin
65.12%
EPS (Latest Qtr)
₹22.23
EPS (TTM)
₹62.28

Balance Sheet & Liquidity

Debt/Equity
2.74
Quick Ratio
3.60
Current Ratio
4.68
Debt
₹283.59 Cr
Total Assets
₹12,510.85 Cr
Current Assets
₹7,526.78 Cr
Working Capital
₹5,918.38 Cr

Ownership

Promoter Holding
51.77%
Chg in Prom Hold
-0.06%
FII / Inst Holding
36.28%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹41,106.73 Cr
Total Revenue (TTM)
₹6,430.65 Cr
EBITDA
₹1,921.53 Cr
Free Cash Flow
₹536.96 Cr
Operating Cash Flow
₹1,031.39 Cr
Shares Outstanding
₹16.48 Cr
Gross Margin
65.12%
Payout Ratio
28.90%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GLAND Gland Pharma Limited NIFTY_SMALLNSEPHARMA 2,495.00 40.06 ₹41,106.73 Cr 0.81% 13.74% 9.92% 21.43% 9.57%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 785.00 Cr1,209.00 Cr1,373.00 Cr1,545.00 Cr1,537.00 Cr1,402.00 Cr1,406.00 Cr1,384.05 Cr1,424.91 Cr1,505.62 Cr1,487.00 Cr1,695.36 Cr1,742.79 Cr
Cost of Revenue -------462.71 Cr487.95 Cr521.13 Cr-576.65 Cr591.33 Cr
Gross Profit -------921.34 Cr936.96 Cr984.49 Cr-1,118.71 Cr1,151.46 Cr
Operating Expenses 617.00 Cr915.00 Cr1,049.00 Cr1,189.00 Cr1,179.00 Cr1,137.00 Cr1,109.00 Cr657.71 Cr685.20 Cr717.78 Cr1,173.00 Cr791.48 Cr747.10 Cr
Operating Income 130.00 Cr229.00 Cr243.00 Cr251.00 Cr266.00 Cr172.00 Cr203.00 Cr263.63 Cr251.75 Cr266.71 Cr208.00 Cr327.23 Cr404.36 Cr
EBITDA 168.00 Cr294.00 Cr324.00 Cr356.00 Cr359.00 Cr264.00 Cr297.00 Cr418.45 Cr391.54 Cr425.29 Cr314.00 Cr473.70 Cr624.49 Cr
Interest Expense 2.00 Cr5.00 Cr6.00 Cr5.00 Cr10.00 Cr6.00 Cr6.00 Cr22.82 Cr7.45 Cr11.50 Cr8.00 Cr3.93 Cr10.03 Cr
Pretax Income 111.00 Cr261.00 Cr290.00 Cr283.00 Cr298.00 Cr218.00 Cr257.00 Cr299.30 Cr288.33 Cr312.74 Cr284.00 Cr362.13 Cr505.80 Cr
Tax Provision 32.19 Cr67.86 Cr95.70 Cr90.56 Cr104.30 Cr74.12 Cr92.52 Cr94.61 Cr101.79 Cr97.26 Cr99.40 Cr100.65 Cr139.12 Cr
Net Income 79.00 Cr194.00 Cr194.00 Cr192.00 Cr192.00 Cr144.00 Cr164.00 Cr204.69 Cr186.54 Cr215.48 Cr184.00 Cr261.48 Cr366.68 Cr
Diluted EPS 4.7811.7911.7811.6511.688.739.9312.4211.3213.0811.1515.8722.23

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 2,633.00 Cr3,463.00 Cr-3,591.86 Cr5,641.73 Cr5,616.50 Cr6,430.65 Cr
Cost of Revenue ---1,685.43 Cr2,173.09 Cr2,090.38 Cr2,242.93 Cr
Gross Profit ---1,906.43 Cr3,468.64 Cr3,526.12 Cr4,187.72 Cr
Operating Expenses 1,678.00 Cr2,161.00 Cr-1,036.32 Cr2,472.55 Cr2,635.07 Cr2,981.84 Cr
Operating Income 860.00 Cr1,203.00 Cr-870.11 Cr996.09 Cr891.05 Cr1,205.88 Cr
EBITDA 955.00 Cr1,302.00 Cr-1,207.61 Cr1,498.90 Cr1,482.53 Cr1,921.53 Cr
Interest Expense 7.00 Cr3.00 Cr-6.29 Cr21.79 Cr42.00 Cr33.28 Cr
Pretax Income 993.00 Cr1,335.00 Cr-1,054.58 Cr1,132.54 Cr1,062.66 Cr1,464.58 Cr
Tax Provision 218.46 Cr333.75 Cr-273.54 Cr360.08 Cr364.13 Cr437.26 Cr
Net Income 773.00 Cr997.00 Cr-781.04 Cr772.46 Cr698.53 Cr1,027.32 Cr
Diluted EPS 49.8860.94-47.4346.8942.4062.28

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 4,086.00 Cr6,496.00 Cr-8,777.53 Cr10,661.25 Cr11,224.92 Cr12,510.85 Cr
Current Assets ---6,900.81 Cr5,645.15 Cr6,782.94 Cr7,526.78 Cr
Cash & Equivalents ---1,908.89 Cr357.09 Cr2,556.19 Cr3,359.11 Cr
Inventory ---1,945.30 Cr1,655.24 Cr1,685.22 Cr1,743.89 Cr
Receivables ---871.39 Cr1,558.69 Cr1,516.53 Cr1,891.38 Cr
Total Liabilities ---818.81 Cr1,937.40 Cr2,074.18 Cr2,152.90 Cr
Current Liabilities ---729.13 Cr1,398.36 Cr1,564.85 Cr1,608.40 Cr
Long Term Debt ---3.26 Cr106.54 Cr77.66 Cr69.92 Cr
Total Debt 5.00 Cr4.00 Cr-4.45 Cr372.17 Cr313.73 Cr283.59 Cr
Total Equity 3,647.00 Cr5,903.00 Cr-7,958.72 Cr8,723.84 Cr9,150.74 Cr10,357.95 Cr
Shares Outstanding ---16.47 Cr16.47 Cr16.48 Cr16.48 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 701.00 Cr605.00 Cr-363.97 Cr996.80 Cr914.73 Cr1,031.39 Cr
Investing Cash Flow -761.00 Cr-1,520.00 Cr-1,208.19 Cr-1,756.91 Cr1,704.74 Cr137.73 Cr
Financing Cash Flow -7.00 Cr1,238.00 Cr-14.92 Cr-799.42 Cr-433.48 Cr-416.97 Cr
Capital Expenditure -171.00 Cr-228.00 Cr--223.12 Cr-398.26 Cr-394.17 Cr-494.43 Cr
Free Cash Flow 530.00 Cr377.00 Cr-140.85 Cr598.54 Cr520.56 Cr536.96 Cr
Net Change in Cash -67.00 Cr323.00 Cr-1,587.08 Cr-1,559.53 Cr2,185.99 Cr752.14 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---53.1%61.5%62.8%65.1%
Operating Margin % 32.7%34.7%-24.2%17.7%15.9%18.8%
Net Margin % 29.4%28.8%-21.7%13.7%12.4%16.0%
ROE % 21.2%16.9%-9.8%8.9%7.6%9.9%
ROCE % ---10.8%10.8%9.2%11.1%

Shareholding Pattern

Insiders
51.77%
Institutions
36.28%
Public Float
75.22%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GLAND

Google News Sat, 11 Jul 2026

Gland Pharma: What Should You Do? - BusinessLine

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPQUU2ajQwZHBleko5Z3B3TDZRNG1KQm45clNYZkNBUzFocVpSQjFJWDNRQjdSTF9fNWNCdnNnNzdtRDVsWUF4Y0dING1QV002Q2ZLQXk2VTBqWmdWU29aYTRZVFZvdHAtZGZCT1RINGhNeW9jU0tZUk1mWEg4LTIyQVBUaGFEX3dfUDcxRT…

Google News hu, 25 Jun 2026

GLAND Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFA4VWQ5SFZPLWdUV3BiUjEyMC1heXRSSWRpbl9GVmdfbTJabElSOUMxQ2xWeG9XX242UlMzX1d0amVPYkZ2d00zbTl3VFAtLWhKUVE5ZVlUa0U5RlJCSWszTEhqX2w2eEEyYmZBQVctOHBRakdGcUVR?oc=5" target="_blank">GLAND F…

Google News Wed, 24 Jun 2026

Bagadia lists five breakout stock picks after market rebound - MSN

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNUGR2MF90RExMY1BvT2N1XzdlNjktRWlKVThJQktwYm5tOVJWdFA3SDJMaWxMcXlPdEFPRFlEUlhlbklOYmpEUmRoY2x5Ums3R3JmZy1MOVZTNGdIcVlRSnFnSkhQMmVqdEQ5TnI0c0xSZjJ6VkNuQVJmdEJzcGJOOF9FZHlQSkNpdGRlZ0…

Google News ue, 19 May 2026

Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNNFJ5Zkl5TEVMak1adXd3UXhaaGVJUHJDWmtwOERiTG5PenM2bmxtTmtyVkxVR3R6YWxzUnBaNTVheFlTcTlSSWpLYXBSeXFhcllsTWo2dkRnVEhudTZLSjJnTmFNeXVNT1VhUTRYNUtycnNwd0c4eXZFNWFBeFRHNmQ4NFFnRDB4dllpZm…

Google News ue, 30 Jun 2026

HOT STOCKS: SHILPAMED Hits All-Time High; WSTCSTPAPR, CGCL, ARVIND, GLAND Lead Gainers; MAHSEAMLES Slips Below 100-DMA While CANFINHOME, SCHAEFFLER Climb Above 50-SMA - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMingJBVV95cUxNMHdwM0Fac2RfRWJHMm9OMDRTOXJJaXVqZHJWWV9fcHlvd3dZZXlURGJ0OFFnUnhmVUpzQkdZay1qTEJNVDZYOXJZMXZuUWZqWTNJcWJhNHVpbDM2LUIwQmxTNWJyd052T3YwRHo5eWlpdnhyajd1X3Z3bnM0V0F5ekU4c0ZkNzlXcU96NU…

Google News Mon, 18 May 2026

Spider silk lab creates immortal silkworm cells for potential future drugs - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbnItcG53VmtvS2pLbnFBU2RzcVJvMkl0UlpudUI3R2F3a2VIUGdUZjgzeGU0YklEWlVobk1fWFdTV3lRdVlFM05FQ216RklidTFtTGFjVElmaUZHaEs1UnFOLTAzSjhFRUdYeHVOaEdlN2ZoTlY1Sl9QaVVTUzE2aUxJLUg5QWlZb0t2S3…

GLAND — Frequently Asked Questions

What is the current share price of Gland Pharma Limited (GLAND)?

As of 2026-07-15 09:52 IST, Gland Pharma Limited (GLAND) trades at ₹2,495.00 on NSE. Its 52-week range is ₹1,596.80 to ₹2,550.00.

What is the market capitalisation of GLAND?

Gland Pharma Limited (GLAND) has a market capitalisation of ₹41,106.73 Cr on NSE.

What is the P/E ratio of GLAND?

GLAND trades at a trailing price-to-earnings (P/E) ratio of 40.06. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.91.

Does GLAND pay a dividend?

Gland Pharma Limited (GLAND) currently offers a dividend yield of 0.81%.

What is the return on equity (ROE) of GLAND?

GLAND has a return on equity (ROE) of 9.92%. Its return on capital employed (ROCE) is 13.74%.

Is GLAND a good stock to buy?

This page provides a data-driven analysis of Gland Pharma Limited (GLAND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space